Company intelligence / Profile preview
AliveGen
Thousand Oaks, California, USAalivegen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AliveGen has successfully completed a Phase 1b multiple ascending dose clinical trial for its lead candidate ALG‑801. The study demonstrated safety, tolerability, linear PK exposure, and significant pharmacodynamic responses including muscle gain, fat loss, improved insulin sensitivity, and dual anabolic/anti-resorptive effects on bone. These results support advancement to Phase 2 trials targeting pulmonary arterial hypertension as well as broader metabolic/muscle-wasting conditions. ALG‑801 has received FDA Orphan Drug Designation for PAH.
- Therapeutic areas
- GastroenterologyCardiovascularNephrologyEndocrinologyRare DiseasesNeurology
- Modalities
- Recombinant proteinsFusion proteinsLigand traps (ActRIIA/IIB hybrid ligand trap)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on AliveGen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AliveGen.